Language:

Journal club

Thorax, 2022-04, Vol.77 (4), p.424-424 [Peer Reviewed Journal]

Full text available

Citations Cited by

Title:
Journal club
Author: Nuttall, Amy G
Subjects: Asthma ; Cytokines ; Patients ; Prescriptions ; Questionnaires ; Steroids ; Teenagers
Is Part Of: Thorax, 2022-04, Vol.77 (4), p.424-424
Description: Correspondence to Dr Amy G Nuttall, Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8XP, UK; amynuttall@doctors.org.uk Dupilumab in moderate-to-severe asthma: good outcomes in children Dupilumab, a monoclonal antibody that blocks interleukin 4 (IL-4) and interleukin 13 (IL-13), the principal mediators of inflammation in children with asthma, is now approved for treatment of asthma in adults and adolescents. Long-term dupilumab exposure was well tolerated with the number of treatment-emergent adverse events similar to parent trials and only rarely led to drug discontinuation (2%–6%; 1–4 patients per 100 patient-years). Reducing oral corticosteroids following benralizumab initiation in adults with severe asthma: can be done quicker than you think Many people with severe asthma require oral corticosteroids (OCS) for symptom control, but this therapy is associated with systemic side effects and adrenal suppression.
Publisher: London: BMJ Publishing Group LTD
Language: English
Identifier: ISSN: 0040-6376
EISSN: 1468-3296
DOI: 10.1136/thoraxjnl-2022-218881
Source: ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Searching Remote Databases, Please Wait